Evidence map›Paper›PMID 37092498›Full record

ArticleMedical sciences (Basel, Switzerland)2023

Two New Cases of Bachmann-Bupp Syndrome Identified through the International Center for Polyamine Disorders.

Julianne Michael, Elizabeth VanSickle, Marlie Vipond, Abby Dalman, Jeremy Prokop, Charles E Schwartz, Surender Rajasekaran, André S Bachmann, Magalie Barth, Clément Prouteau and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Genetic Diagnosis and Discovery Enabled by Large Language Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Structural Insights into the Mechanisms Underlying Polyaminopathies.International journal of molecular sciences · 2024
    Review
  4. Bachmann-Bupp syndrome and treatment.Developmental medicine and child neurology · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Julianne MichaelCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.ORCID 0000-0003-1244-1818
Elizabeth VanSickleCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.
Marlie VipondCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.
Abby DalmanCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.
Jeremy ProkopCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.
Charles E SchwartzInternational Center for Polyamine Disorders, Grand Rapids, MI 49503, USA.
Surender RajasekaranCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.
André S BachmannInternational Center for Polyamine Disorders, Grand Rapids, MI 49503, USA.ORCID 0000-0002-6510-8560
Magalie BarthDepartment of Biochemistry and Genetics, Angers University Hospital Center, 49100 Angers, France.
Clément ProuteauDepartment of Biochemistry and Genetics, Angers University Hospital Center, 49100 Angers, France.ORCID 0000-0002-2986-5599
Yotam AlmagorMeuhedet Healthcare, Jerusalem 9957520, Israel.
Lina BerkunShaare Zedek Medical Center, Medical Genetics Institute, Jerusalem 9103102, Israel.
Gheona AlterescuShaare Zedek Medical Center, Medical Genetics Institute, Jerusalem 9103102, Israel.
Caleb P BuppCorewell Health and Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.
Helen DeVos Children's Hospital · USMichigan State University · USShaare Zedek Medical Center · ILUniversité d'Angers · FR

Funding

Leveraging modulation of polyamine metabolism for therapeutic advantage in genetic disordersR01HD110500 · NICHD · MICHIGAN STATE UNIVERSITY · PI ANDRE S BACHMANN, Caleb Bupp · 2023 to 2026
$2.7M
NICHD NIH HHS R01 HD110500
6 · The paper itself

Abstract

Recent identification of four additional polyaminopathies, including Bachmann-Bupp syndrome, have benefited from previous research on Snyder-Robinson syndrome in order to advance from research to treatment more quickly. As a result of the discovery of these conditions, the potential for treatment within this pathway, and for other possible unidentified polyaminopathies, the International Center for Polyamine Disorders (ICPD) was created to help promote understanding of these conditions, research opportunities, and appropriate care for families. This case study provides insights from two new patients diagnosed with Bachmann-Bupp syndrome, further expanding our understanding of this ultra-rare condition, as well as a general discussion about other known polyaminopathies. This work also presents considerations for collaborative research efforts across these conditions, along with others that are likely to be identified in time, and outlines the role that the ICPD hopes to fill as more patients with these polyaminopathies continue to be identified and diagnosed.

Indexed as

EflornithinePolyaminesHumansEflornithinePolyaminesBachmann–Bupp Syndrome (BABS)International Center for Polyamine Disorders (ICPD)polyamineSnyder–Robinson Syndrome (SRS)α-difluoromethylornithine (DFMO)

Identifiers

PMID37092498
PMCPMC10123676
OpenAlexW4362557428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.